Cargando…
Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines
We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish and Indian females, respectivel...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021830/ https://www.ncbi.nlm.nih.gov/pubmed/32128255 http://dx.doi.org/10.1038/s41541-020-0165-x |
_version_ | 1783497955189194752 |
---|---|
author | Mariz, Filipe Colaço Bender, Noemi Anantharaman, Devasena Basu, Partha Bhatla, Neerja Pillai, Madhavan Radhakrisna Prabhu, Priya R. Sankaranarayanan, Rengaswamy Eriksson, Tiina Pawlita, Michael Prager, Kristina Sehr, Peter Waterboer, Tim Müller, Martin Lehtinen, Matti |
author_facet | Mariz, Filipe Colaço Bender, Noemi Anantharaman, Devasena Basu, Partha Bhatla, Neerja Pillai, Madhavan Radhakrisna Prabhu, Priya R. Sankaranarayanan, Rengaswamy Eriksson, Tiina Pawlita, Michael Prager, Kristina Sehr, Peter Waterboer, Tim Müller, Martin Lehtinen, Matti |
author_sort | Mariz, Filipe Colaço |
collection | PubMed |
description | We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish and Indian females, respectively. We used a semi-automated Pseudovirion-Based Neutralization Assay and observed significantly higher HPV16/18 peak ab-levels in bivalent as compared to quadrivalent vaccine recipients. Bivalent vaccine induced cross-neutralizing HPV31/33/45/52/58 antibodies significantly more frequently and to higher levels than the quadrivalent vaccine. The correlation of bivalent vaccine-induced HPV45 ab-levels with HPV16/18 ab-levels was stronger than that of corresponding quadrivalent vaccine-induced ab-levels, suggesting a qualitatively different cross-reactive response. Our findings on the comparison of the immunogenicity of two HPV vaccine tested in two different populations indicate that further head-to-head studies are warranted. |
format | Online Article Text |
id | pubmed-7021830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-70218302020-03-03 Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines Mariz, Filipe Colaço Bender, Noemi Anantharaman, Devasena Basu, Partha Bhatla, Neerja Pillai, Madhavan Radhakrisna Prabhu, Priya R. Sankaranarayanan, Rengaswamy Eriksson, Tiina Pawlita, Michael Prager, Kristina Sehr, Peter Waterboer, Tim Müller, Martin Lehtinen, Matti NPJ Vaccines Brief Communication We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish and Indian females, respectively. We used a semi-automated Pseudovirion-Based Neutralization Assay and observed significantly higher HPV16/18 peak ab-levels in bivalent as compared to quadrivalent vaccine recipients. Bivalent vaccine induced cross-neutralizing HPV31/33/45/52/58 antibodies significantly more frequently and to higher levels than the quadrivalent vaccine. The correlation of bivalent vaccine-induced HPV45 ab-levels with HPV16/18 ab-levels was stronger than that of corresponding quadrivalent vaccine-induced ab-levels, suggesting a qualitatively different cross-reactive response. Our findings on the comparison of the immunogenicity of two HPV vaccine tested in two different populations indicate that further head-to-head studies are warranted. Nature Publishing Group UK 2020-02-14 /pmc/articles/PMC7021830/ /pubmed/32128255 http://dx.doi.org/10.1038/s41541-020-0165-x Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Brief Communication Mariz, Filipe Colaço Bender, Noemi Anantharaman, Devasena Basu, Partha Bhatla, Neerja Pillai, Madhavan Radhakrisna Prabhu, Priya R. Sankaranarayanan, Rengaswamy Eriksson, Tiina Pawlita, Michael Prager, Kristina Sehr, Peter Waterboer, Tim Müller, Martin Lehtinen, Matti Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines |
title | Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines |
title_full | Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines |
title_fullStr | Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines |
title_full_unstemmed | Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines |
title_short | Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines |
title_sort | peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent hpv vaccines |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021830/ https://www.ncbi.nlm.nih.gov/pubmed/32128255 http://dx.doi.org/10.1038/s41541-020-0165-x |
work_keys_str_mv | AT marizfilipecolaco peakneutralizingandcrossneutralizingantibodylevelstohumanpapillomavirustypes616183133455258inducedbybivalentandquadrivalenthpvvaccines AT bendernoemi peakneutralizingandcrossneutralizingantibodylevelstohumanpapillomavirustypes616183133455258inducedbybivalentandquadrivalenthpvvaccines AT anantharamandevasena peakneutralizingandcrossneutralizingantibodylevelstohumanpapillomavirustypes616183133455258inducedbybivalentandquadrivalenthpvvaccines AT basupartha peakneutralizingandcrossneutralizingantibodylevelstohumanpapillomavirustypes616183133455258inducedbybivalentandquadrivalenthpvvaccines AT bhatlaneerja peakneutralizingandcrossneutralizingantibodylevelstohumanpapillomavirustypes616183133455258inducedbybivalentandquadrivalenthpvvaccines AT pillaimadhavanradhakrisna peakneutralizingandcrossneutralizingantibodylevelstohumanpapillomavirustypes616183133455258inducedbybivalentandquadrivalenthpvvaccines AT prabhupriyar peakneutralizingandcrossneutralizingantibodylevelstohumanpapillomavirustypes616183133455258inducedbybivalentandquadrivalenthpvvaccines AT sankaranarayananrengaswamy peakneutralizingandcrossneutralizingantibodylevelstohumanpapillomavirustypes616183133455258inducedbybivalentandquadrivalenthpvvaccines AT erikssontiina peakneutralizingandcrossneutralizingantibodylevelstohumanpapillomavirustypes616183133455258inducedbybivalentandquadrivalenthpvvaccines AT pawlitamichael peakneutralizingandcrossneutralizingantibodylevelstohumanpapillomavirustypes616183133455258inducedbybivalentandquadrivalenthpvvaccines AT pragerkristina peakneutralizingandcrossneutralizingantibodylevelstohumanpapillomavirustypes616183133455258inducedbybivalentandquadrivalenthpvvaccines AT sehrpeter peakneutralizingandcrossneutralizingantibodylevelstohumanpapillomavirustypes616183133455258inducedbybivalentandquadrivalenthpvvaccines AT waterboertim peakneutralizingandcrossneutralizingantibodylevelstohumanpapillomavirustypes616183133455258inducedbybivalentandquadrivalenthpvvaccines AT mullermartin peakneutralizingandcrossneutralizingantibodylevelstohumanpapillomavirustypes616183133455258inducedbybivalentandquadrivalenthpvvaccines AT lehtinenmatti peakneutralizingandcrossneutralizingantibodylevelstohumanpapillomavirustypes616183133455258inducedbybivalentandquadrivalenthpvvaccines |